Predictive Factors of Endoscopic Mucosal Healing in Quiescent Ulcerative Colitis

Completed

• Conditions: Ulcerative Colitis

• Registration Number: NCT02640391
• Lead Sponsor: Kyungpook National University Hospital

Brief Summary

The purpose of this study is to determine whether fecal calprotectin, fecal immunochemical test, and Rome III criteria for irritable bowel syndrome (IBS) can predict mucosal healing in patients with quiescent ulcerative colitis (UC).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-12-15
• Study First Submitted QC: 2015-12-22
• Study First Posted: 2015-12-29
• Study Start: 2016-01
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-12
• Last Update Posted: 2019-08-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 127

Inclusion Criteria

• Patients with ulcerative colitis who have no change of medication for at least 6 months
• Patients with ulcerative colitis who are in remission (Mayo score <3)
• Patients with ulcerative colitis who will undergo colonoscopy for surveillance or mucosal healing check-up

Exclusion Criteria

• Patients who refuse to participate
• Patients who have a history of colectomy
• Patients who have instinal stricture or perforation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fecal calprotectin	1 week
Mucosal healing	1 week	Endoscopic Mayo subscore \<1
Fecal immunochemical test	1 week

Secondary Outcome Measures

Name	Time	Method
Rome III criteria for IBS	1 week

Trial Locations

Locations (1)

Keimyung University Dongsan Medical Center; 🇰🇷 Daegu, Korea, Republic of